melanoma, osteosarcoma, and neuroblastoma. This increased antimetastatic-tumor activity has been seen in multiple organs, including blood, livers, and lungs. Though equal anti-tumor effi cacy is found in both primary and metastatic tumors in lungs and livers, the profi le of immune cells at the primary and metastatic tumor sites following IL12 gene therapy treatment are vastly different. Such a difference also occurs between tumor-targeted IL12 and wildtype IL12 gene therapy. Interestingly, some types of immune suppressive cells were signifi cantly increased in metatatic tumors but reduced in primary tumors by the same IL12 treatment in the same mouse. The increased population of key immune suppressive cells does not affect the antitumor effi cacy of IL12 and tumor-targeted IL12 therapy, challenging the conventional paradigm that these immune suppressive cells only play either pro-or anti-tumor immune roles. These results are intriguing and could help to further understand the anti-tumor activities of tumor-targeted immune therapies.
The majority of mesothelioma has the wild-type p53 gene but possesses a homologous deletion at the INK4A/ARF locus containing the p14 and the p16 genes, which leads to decreased p53 functions despite the wild-type geneotype. These genetic changes induced down-regulated p53 expression and phosphorylated pRb through CDKs, which consequently promotes cell cycle. We thereby tested a possible apoptosis induction with adenoviruses expressing the wildtype p53 gene (Ad-p53) and Ad defective of E1B55kDa molecules (Ad-delE1B55). Both Ad-p53 and Ad-delE1B55 up-regulated p53 expression levels and induced the phosphorylation at Ser 15 and then at Ser 46. Activated p53 pathways further down-regulated Mdm2 and up-regulated p21, which dephosphorylated pRb at Ser 795. These data suggested that Ad-p53 and Ad-delE1B55 restored the p53 functions and inhibited cell cycle progression. Transduction of mesothelioma cells with Ad-53 or Ad-delE1B55 activated caspase pathways and induced apoptotic cell death. Moreover, the transduction augmented susceptibility of mesothelioma cells to the fi rst-line chemotherapeutic agents, cisplatin and pemetrexed. The third generation of bisphosphonates, currently used for osteoporosis and malignancy-linked hypercalcemia, also produced cytotoxic effects on mesothelioma by inhibiting a prenylation process of small G proteins, which resulted in loss of the activities. Cell death by the bisphosphoates was accompanied by up-regulated p53 expression and p53 phosphorylation, indicating that the p53 pathways were activated. A combinatory use of Ad-p53 and the bisphosphonates produced cytotoxicity greater than administration of each agent. These data collectively indicates that up-regulation of p53 in mesothelioma is a therapeutic strategy and a combinatory use of chemotherapeutic agents or small G protein inhibitors has a possible clinical feasibility.
Angiotensin Type 2 Receptors Inhibit Growth of Hepatocellular Carcinoma through Cell Cycle Arrest and Apoptosis
Hongyan Du, 1 Yangling Zhang, 1 Nana Pei, 1 Yongxin Gao, 3 Baihong Chen, 1 Colin Sumners, 2 Ming Li, 1 Hongwei Li. 1 1 School of Biotechnology, Southern Medical University, Guangzhou, China; 2 Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL; 3 Malcom Randall Veterans Affairs Medical Center, Gainesville, FL. The renin-angiotensin system (RAS) plays a major role in vascular homeostasis, regulating blood pressure and blood fl ow by modulating vascular tone. Disorders affecting the RAS contribute to the pathophysiology of most cardiovascular diseases. Angiotensin II (AngII), the major bioactive peptide of the RAS, has important pathophysiologic roles participating in cardiac hypertrophy, vascular cell proliferation, infl ammation, and tissue remodeling acting through its G-protein-coupled receptors (GPCRs), Type 1 (AT1R) and Type 2 (AT2R). AT1R are located in almost all tissues, including the vascular wall, brain, kidney, lung, liver, adrenal gland and hypophysis, but AT2R are present mainly in neonates and young animals. It has been reported that AT1R expression is up-regulated in many cancers, such as breast cancer, pancreatic cancer, skin neoplasms, breast-, pancreatic-, prostate-, bladder-and lung cancer, and this suggests that Ang II plays critical roles in tumorigenesis and metastasis via AT1R. Furthermore, numerous studies have shown antigrowth and antiproliferative effects of Ang II via AT2R, in opposition to actions of this peptide via the AT1R. Hepatocellular carcinoma (HCC) is a major health concern worldwide, especially in Asia, ranking fi fth in occurrence amongst common cancers and the third-most common cause of cancer-related death. Thus, fi nding a new therapy for HCC is of high priority. This study demonstrated that AT2R overexpression caused inhibition of growth and stimulation of apoptosis in hepatocellular carcinoma cells. A recombinant adenoviral vector expressing AT2R (Ad-G-AT2R-EGFP) was transduced into two HCC cell lines, SMMC7721 and Bel7402. Following transduction, apoptosis was analyzed by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling staining. The data indicate that increased expression of AT2R alone resulted in apoptosis in the HCC cell lines. Furthermore, AT2R overexpression in SMMC7721 cells inhibited cell proliferation with a signifi cant reduction of S-phase cells and an enrichment of G1-phase cells. This data demonstrates that increased AT2R expression in HCC cells may have potential therapeutic applications for this disease, and suggest that AT2R is a promising novel target gene for HCC gene therapy. Our previous studies demonstrated that AT2R overexpression induces apoptosis of prostate cancer cells, but not of normal prostate cells. However, the mechanism has not been fully characterized. This study was aimed to identify regulatory genes that are related to the apoptotic pathway in prostate cancer cells. Recombinant adenoviral vectors expressing AT2R (Ad5-CMV-AT2R-EGFP) or the control S187 HEMATOLOGIC AND IMMUNOLOGIC GENE & CELL THERAPY II protein GFP (Ad5-CMV-EGFP) were transduced into androgenindependent prostate cancer (DU145) cells, respectively. Total cellular RNA was extracted at 48 hours post-transduction. Expression of 84 genes related to the apoptotic pathway was analyzed using the RT2 profi ler PCR Array System. The results showed that the tumor necrosis factor receptor (TNFRSF10B), genes of the Bcl-2 family (BAG3, BNIPI, and HRK), and p53 binding protein were upregulated while TNFS10 of the tumor necrosis factor ligand family was downregulated in the AT2R overexpressing cells compared to the controls. Thus, our study identifi ed seven genes that may be involved in AT2R induced apoptosis in prostate cancer cells. This information may lead to a better understanding of the mechanism of AT2R-induced apoptosis of these cells. p16-mediated inhibition of cancer cell proliferation and tumor suppression have been studied before; the common consensus is that p16's cell-cycle arrest function plays a primary role in these actions, with some additional apoptotic induction by p16. However, other effects of p16 that may potentially contribute to p16-mediated anti-tumor ability have not been well studied. The emerging data including ours demonstrated that p16 contributes its anti-cancer ability by inducing tumor cells to senescence. In addition, we reported in this study that adenoviral-mediated p16 gene transfer (Adp16) inhibits breast cancer cell growth by inhibiting the VEGF signaling pathway and angiogenesis. We used Adp16 and breast cancer cell line MDA-MB-231 as the model to simultaneously analyze all these p16's anti-tumor functions. We demonstrated that adenoviral-mediated p16 expression exhibited multiple anti-tumor functions by simultaneously suppressing in vitro growth and in vivo angiogenesis of breast cancer cells, blocking cell division, as well as inducing senescence and apoptosis. The in vivo study implies that p16's effect on anti-angiogenesis may play a more signifi cant role than its anti-cell proliferation in the overall suppression of tumor growth. These results suggest, for the fi rst time, that Adp16-mediated tumor suppression results from a combination of p16's multiple anti-tumor functions including p16's well-known anti-proliferation/ cell division function, apoptotic and senescence induction function, and its lesser-known/under-investigated anti-angiogenesis function. These combined results strongly indicate that p16 gene therapy has a multi-module platform with different anti-tumor functions; therefore, this study justifi es and promotes the viral-mediated p16 gene therapy as a promising and powerful treatment approach for cancer patients due to p16's multiple anti-tumor functions.
Effects of Angiotensin Type 2 Receptor Overexpression on Gene Expression Profi les in Human Prostate Cancer Cells

Inhibition of Breast Tumor Growth by Adenoviral-Mediated p16 Gene Transfer Via Combined Effects of Cell Cycle Arrest, Senescence and Apoptotic Induction, and Angiogenesis Inhibition
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Production and Evaluation of Lenti-hWASP-Vectors for Wiscott Aldrich Syndrome
Matthew Wielgosz, 1 Rachel Koldej, 1 Gael Carney, 1 Rob Throm, 1 John Gray, 1 Arthur Nienhuis. 1 1 Experimental Hematology, St. Jude Children's Research Hospital, Memphis, TN.
Retroviral vector transduction of hematopoietic stem cells has proved corrective for patients with severe immunodeficiencies (SCID). However, γ-onco-retroviral vectors have caused leukemias in ≥10% of treated patients, due to insertional mutagenesis into proto oncogenes such as LMO2. While insertional mutagenesis is a concern for lentiviral vectors as well, lentiviruses insert less frequently near transcriptional start sites and their capacity to hold larger genomes for the incorporation of safety elements such as insulators are signifi cant advantages. Here we describe the production of insulated, selfinactivated, lentiviral vectors encoding the human Wiscott Aldrich Syndrome Protein (hWASP) gene from full producer cell clones derived using concatemeric array transfection (Throm et.al. Blood. 2009. 113:5104-5110) . Unconcentrated titers of select producer clones containing the 5' 400 bp of the chicken hypersensitive site 4 (cHS4) insulator, or a 650 bp cHS4 element (the 5' 250 bp core of the cHS4 1.2 Kb insulator fused to the last 3' 400 bp of the cHS4 1.2 Kb insulator) averaged 3x10 7 IU/ml, as determined by Southern analyses. One insulated producer clone yielded titers ≥1x10 8 IU/ml. Vector preps from these producers transduced early human CFU-C progenitors at 20, 32, and 43%, with MOIs of ∼32, 29, and 78 respectively, as scored by PCR amplifi cation of endogenous and vector-derived hWASP DNA. Transiently prepared hWASP lentiviral vector transduced ∼17% of early CFU-C progenitors at an MOI of ∼20. A concentrated vector prep derived from one of the full producer clones transduced 52% of early CFU-C progenitors, at an MOI of ∼320 without affecting cell viability, while a transiently-derived GFP lentiviral prep transduced 53% of early CFU-C progenitors at an MOI of ∼11 (as assessed via fl ourescence microscopy). These results demonstrate that full hWASP producer vectors transduce early human progenitors at levels comparable to transiently-derived hWASP vector, and can be used at high MOIs without signifi cantly impacting cell viability. We also examined the relative safety of uninsulated, 400bp, and 650bp cHS4 insulated, proviral hWASP vectors containing the MND promoter from a retroviral LTR for hWASP expression, in the context of an LMO2 activation assay, in Jurkat cell clones (Ryu et. al. Blood 2008 . 111:1866 -1875 . We found that a vector genome containing an internal MND promoter inserted at the site of vector insertion of an X-SCID patient (upstream of Exon 1) activated LMO2, whereas activation by vector genomes with cHS4 insulator elements in the LTRs was low. In addition, LMO2 protein levels for Jurkat clones containing insulated vector genomes were lower than for Jurkat clones with an uninsulated genome. In summary, we have developed full lentiviral hWASP producer cell clones that yield unconcentrated titers ∼3x10 7 IU/ml, and transduce early human CD34 + CFU-C progenitors at levels comparable to transiently-derived vector. In addition, insulated proviral forms of these vectors can reduce LMO2 mRNA and protein levels over the non-insulated vector, making these hWASP producer vectors ideal candidates for use in clinical trials.
